Press Releases

2026

Jul 20, 2026

Orasis Pharmaceuticals Doubles Down on Eye Care Professionals, Not Telehealth, as QLOSI® Refills Reach 49.1%

Read More

Jul 15, 2026

Orasis Pharmaceuticals Announces Australia Submission of a New Drug Application for BESKA for the Treatment of Presbyopia

Read More

Jan 27, 2026

New Data Demonstrate Qlosi™ Is Pupil Selective With Ciliary Muscle Movement No Different Than A Balanced Salt Solution (BSS) Control

Read More

2025

Nov 13, 2025

Orasis Pharmaceuticals Expands Access To Qlosi™ With New Starter Packs For Eye Care Professionals, Bolstering Commercial Rollout

Read More

Apr 07, 2025

Orasis Pharmaceuticals Announces Novel Corrective Eyedrop for Presbyopia, Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, Now Available to Prescribe in the U.S.

Read More

2024

Oct 16, 2024

Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in Korea

Read More

Oct 08, 2024

Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%

Read More

2023

Oct 17, 2023

Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia

Read More

Feb 20, 2023

FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia

Read More

Jan 03, 2023

Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Read More